Triple negative breast cancer: unmet medical needs

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2011-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-010-1293-1PMID 21161370PMCID PMC3244802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.

  2016cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

  2010cited by this paper
• Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis (Journal of the National Comprehensive Cancer Network (2009) 7, (1060-1096))

  2010cited by this paper
• Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004

  2009cited by this paper
• Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

  2009cited by this paper
• Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• dose escalation study

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

  2009cited by this paper
• Triple-negative breast cancer: novel therapies and new directions.

  2009cited by this paper
• Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer

  2009cited by this paper
• Pattern of metastatic spread in triple-negative breast cancer

  2009cited by this paper
• Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).

  2009cited by this paper
• Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

  2009cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009influential reference
• Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

  2009influential reference
• Epidemiology of basal-like breast cancer

  2008cited by this paper
• Basal-like subtype and BRCA1 dysfunction in breast cancers

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Platinum-based chemotherapy in triple-negative breast cancer.

  2008cited by this paper
• Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.

  2008cited by this paper
• Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

  2008cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Triple-Negative Breast Cancer: Risk Factors to Potential Targets

  2008influential reference
• Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients

  2007cited by this paper
• Triple-negative breast cancer: therapeutic options.

  2007influential reference
• Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

  2007cited by this paper
• Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers

  2007cited by this paper
• Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

  2007cited by this paper
• Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

  2007cited by this paper
• Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer

  2007cited by this paper
• Triple negative tumours: a critical review

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• P57 The PARP1 gene is over-expressed in triple negative breast cancer

  2007cited by this paper
• Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study

  2007cited by this paper
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007influential reference
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

  2006influential reference
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Metaplastic breast carcinomas are basal‐like tumours

  2006cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR

  2006cited by this paper
• Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

  2006cited by this paper
• Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

  2006cited by this paper
• A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors

  2005cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Typical medullary breast carcinomas have a basal/myoepithelial phenotype

  2005cited by this paper
• High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004influential reference
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003influential reference
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer.

  2000cited by this paper
• Breast Cancer: Metastatic Patterns and Their Prognosis

  1988cited by this paper

• In silico design and in vitro validation of a multi-epitope peptide vaccine targeting triple-negative breast cancer

  2025cites this paper
• Molecular Subtypes and Survival Patterns in Female Breast Cancer: Insights from a 12-Year Cohort

  2025cites this paper
• Adding Neoadjuvant Immunotherapy to Chemotherapy in Non-Metastatic Triple-Negative Breast Cancer: A Propensity-Matched Cohort Study from a Tertiary Cancer Center

  2025cites this paper
• Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors

  2025cites this paper
• Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective

  2025cites this paper
• The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials

  2025cites this paper
• Monitoring Pharmacological Treatment of Breast Cancer with MRI

  2025cites this paper
• Targeting the Beast Along My Illness Trajectory: A Qualitative Study of Females With Triple-Negative Breast Cancer

  2025cites this paper
• Prognostic significance of body mass index in patients with triple negative breast cancer: A retrospective observational study

  2025cites this paper
• Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors

  2025cites this paper
• 4T1 Cell Membrane Biomimetic Nanovehicle for Enhanced Breast Cancer Treatment.

  2024cites this paper
• Lespedeza bicolor root extract exerts anti-TNBC potential by regulating FAK-related signalling pathways.

  2024cites this paper
• FTIR Reveals Novel Insights into 5‐FU and Carmofur's Impact on Breast Cancer Cells

  2024cites this paper
• Enhanced expression of galectin‐9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy

  2024cites this paper
• Exosomal circRHCG promotes breast cancer metastasis via facilitating M2 polarization through TFEB ubiquitination and degradation

  2024cites this paper
• NRF3 suppresses the malignant progression of TNBC by promoting M1 polarization of macrophages via ROS/HMGB1 axis

  2024cites this paper
• Next-generation biomarkers for prognostic and potential therapeutic enhancement in Triple negative breast cancer.

  2024cites this paper
• Thrombin confers chemotherapeutic resistance by promoting transcriptional induction and post-translational stabilization of pro-survival MCL1 in TNBC

  2024cites this paper
• Comparative efficacy of Jaungo, a traditional herbal ointment, and a water-in-oil type non-steroidal moisturizer for radiation-induced dermatitis in patients with breast cancer: a prospective, randomized, single-blind, pilot study

  2023cites this paper
• Updated Biomarkers for TNBC in African vs. Caucasian American Women

  2023influential citation
• MiR‐526b targets lncRNA SLC16A1‐AS1 to suppress cell proliferation in triple‐negative breast cancer

  2023cites this paper
• Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer

  2023cites this paper
• A BRIEF OVERVIEW OF SEVERAL RECENT ADVANCEMENTS OF TARGETED-THERAPIES AND ANTIBODY-CONJUGATE DRUGS FOR ADVANCED TRIPLE-NEGATIVE BREAST CANCER

  2023cites this paper
• Biogenic synthesis of gold nanoparticles using dual extract of tulsi-Vinca for breast cancer tumor regression in mice.

  2023cites this paper
• Targeting Breast Cancer: An Overlook on Current Strategies

  2023cites this paper
• Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer

  2023cites this paper
• Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients

  2023cites this paper
• Cardamom Essential Oil Extract Suppress the Progression of Triple-Negative Breast Cancer 4T1 Cell Line

  2023cites this paper
• The Effects of Omega-3 Polyunsaturated Fatty Acids on Breast Cancer as a Preventive Measure or as an Adjunct to Conventional Treatments

  2023cites this paper
• Peptide L1H9 derived from the interaction of structural human rhomboid family 1 and 80-kDa subunit of Ku antigen sensitizes breast cancer to chemoradiotherapy

  2023cites this paper
• Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model

  2023cites this paper
• Citrus aurantium Peel Extract Combined with Doxorubicin-Induced ROS-driven Cell Cycle Arrest and Apoptosis of Triple-Negative Breast Cancer Cells

  2023cites this paper
• Mamografía con medio de contraste: definiendo los patrones imagenológicos de los subtipos moleculares del cáncer de mama

  2023cites this paper
• In Silico Analysis of the Effect of Hydrastis canadensis on Controlling Breast Cancer

  2023influential citation
• Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells

  2023cites this paper
• Targeted inhibition of Wnt signaling with a Clostridioides difficile toxin B fragment suppresses breast cancer tumor growth

  2023cites this paper
• Biomarkers derived from CmP signal network in triple negative breast cancers

  2023cites this paper
• Curdlan/Clay Nanocomposite-Reinforced Alginate Beads as Drug Carriers

  2023cites this paper
• Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment

  2023cites this paper
• Docosahexaenoic acid enrichment of tumor phospholipid membranes increases tumor necroptosis in mice bearing triple negative breast cancer patient-derived xenografts.

  2022cites this paper
• Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer.

  2022cites this paper
• Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple‐negative breast cancer by stabilizing Snail1

  2022cites this paper
• DCE-MRI Performance in Triple Negative Breast Cancers: Comparison with Non-Triple Negative Breast Cancers.

  2022cites this paper
• CircDUSP1 regulates tumor growth, metastasis, and paclitaxel sensitivity in triple‐negative breast cancer by targeting miR‐761/DACT2 signaling axis

  2022cites this paper
• CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer

  2022cites this paper
• The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice.

  2022cites this paper
• Phenanthroindolizidine Alkaloids Isolated from Tylophora ovata as Potent Inhibitors of Inflammation, Spheroid Growth, and Invasion of Triple-Negative Breast Cancer

  2022cites this paper
• ROSIE: RObust Sparse ensemble for outlIEr detection and gene selection in cancer omics data

  2022cites this paper
• Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells

  2022cites this paper
• Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

  2022cites this paper
• One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer

  2022cites this paper
• Hydrogen phosphate selectively induces MDA MB 231 triple negative breast cancer cell death in vitro

  2022cites this paper
• Growth-promoting function of the cGAS-STING pathway in triple-negative breast cancer cells

  2022cites this paper
• Machine learning assisted analysis of breast cancer gene expression profiles reveals novel potential prognostic biomarkers for triple-negative breast cancer

  2022cites this paper
• Relationship between metabolic reprogramming and drug resistance in breast cancer

  2022cites this paper
• A comprehensive review on neurokinin-1 receptor antagonism in breast cancer

  2021cites this paper
• Proteomics study on the effect of combined treatment of electrical pulses and tomato lipophilic extract in the downregulation of proliferating cell nuclear antigen in triple-negative breast cancer cell

  2021cites this paper
• Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

  2021cites this paper
• Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study

  2021cites this paper
• LOCOREGIONAL STAGE ASSESSMENT IN CLINICALLY NODE NEGATIVE BREAST CANCER

  2021cites this paper
• Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple‐negative breast cancer through FRA‐1 regulation

  2021cites this paper
• Prediction of Response to Atezolizumab Plus Nab-Paclitaxel in Unresectable Locally Advanced Triple Negative Breast Cancer (TNBC): the ClinicalUsefulness of PD-L1 mRNA Expression in Plasma-Derived Exosomes

  2021cites this paper
• Role of AMPK and Akt in triple negative breast cancer lung colonization

  2021cites this paper
• Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging.

  2021cites this paper
• Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer

  2021cites this paper
• Snapshot imprinting: rapid identification of cancer cell surface proteins and epitopes using molecularly imprinted polymers

  2021cites this paper
• Polysaccharide-rich extract from Polygonatum sibiricum protects hematopoiesis in bone marrow suppressed by triple negative breast cancer.

  2021cites this paper
• Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer

  2021cites this paper
• An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.

  2021cites this paper
• Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions

  2021cites this paper
• Characterization of Alcohol-Mediated Promotion of Breast Cancer Stem Cells

  2021cites this paper
• Aptamer-guided targeting of the intracellular long-noncoding RNA HOTAIR.

  2021cites this paper
• Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer

  2021cites this paper
• Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

  2021cites this paper
• Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer

  2021influential citation
• Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

  2020cites this paper
• Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort

  2020cites this paper
• Economic evaluation of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

  2020influential citation
• Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

  2020cites this paper
• Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer

  2020influential citation
• Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer

  2020cites this paper
• NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1

  2020cites this paper
• [The first experience of PD-L1 testing of triple negative breast cancer with marker SP142 in Russia].

  2020cites this paper
• Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

  2020cites this paper
• Diagnostik und Therapie des HER2-negativen metastasierten Mammakarzinoms 2020 Empfehlungen für die tägliche Routine (Sponsor: Roche Pharma AG)

  2020cites this paper
• Targeted inhibition of Wnt signaling with a bacterial toxin fragment suppresses breast cancer tumor-initiating/chemo-resistant cells

  2020cites this paper
• Twist1 accelerates tumour vasculogenic mimicry by inhibiting Claudin15 expression in triple‐negative breast cancer

  2020cites this paper
• Unmet Medical Care Needs Due To Payment Difficulty

  2020cites this paper
• BCTT_A_236483 27..35

  2020cites this paper
• LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

  2020cites this paper
• Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer

  2020cites this paper
• Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions

  2020cites this paper
• Crystal engineering of an adenine-decavanadate molecular device towards label-free chemical sensing and biological screening.

  2020cites this paper
• Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer

  2020cites this paper
• Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

  2020cites this paper
• Unveiling Role of MicroRNAs as Treatment Strategy and Prognostic Markers in Triple Negative Breast cancer.

  2020cites this paper
• Synthesis and antibacterial activity of epoxide from hyptolide (Hyptis pectinata (L.) Poit) against Gram-positive and Gram-negative bacteria

  2020cites this paper
• Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer

  2020cites this paper
• Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

  2020cites this paper
• Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer

  2020cites this paper